Evidence map›Paper›PMID 39610475›Full record

ReviewJournal of diabetes and metabolic disorders2024

A closer look at Galectin-3: its association with gestational diabetes mellitus revealed by systematic review and meta-analysis.

Seyed Sobhan Bahreiny, Akram Ahangarpour, Mojtaba Aghaei, Reza Mohammadpour Fard, Mohammad Ali Jalali Far, Tannaz Sakhavarz

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes and metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Seyed Sobhan BahreinyMedicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID 0000-0003-2148-1205
Akram AhangarpourMedicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mojtaba AghaeiStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Reza Mohammadpour FardStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mohammad Ali Jalali FarThalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Tannaz SakhavarzDepartment of Biochemistry, Faculty of Biological Science, Kharazmi University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Gestational diabetes mellitus (GDM) represents a significant metabolic disorder that affects pregnant women worldwide and has negative consequences for both the mother and her offspring. This research aims to investigate the relation between circulating levels of Galectin-3 and the incidence of GDM, and to evaluate its potential as a biomarker for monitoring and early detection of the disease. Methods: A thorough search of the literature has been performed using databases such as Scopus, Web of science, Embase, Cochrane Library and PubMed. The standardized mean difference (SMD) and corresponding confidence intervals (CIs) were used to compute the effect size from individual records and pooled using the Random-effect model. Results: Our meta-analysis synthesized data from 9 studies, encompassing 1,286 participants (533 GDM patients and 753 healthy pregnant controls). The findings demonstrated a considerable increase in Galectin-3 levels among individuals diagnosed with GDM as compared to the healthy control (SMD = 0.929; CI: 0.179-1.679; Conclusion: Increased levels of Galectin-3 exhibit a significant association with GDM, indicating its prospective utility as a biomarker for early detection and risk assessment. Further research is warranted to elucidate its regulation and clinical implications in GDM management. Graphical Abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-024-01461-z.

Indexed as

BiomarkerGalectin-3Gestational diabetes mellitusMeta-analysisSystematic review

Identifiers

PMID39610475
PMCPMC11599495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.